Medicenna Therapeutics Quote - MDNA

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

1.85

Bid

1.82

Offer

1.88

Volume

29,147

1.78 Day's Range 1.98

0.385 52 Week Range 2.98

Market Cap

128.828M

Previous Close

1.84

Open

1.80

Last Trade

100

1.87

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

81,978

Shares Outstanding

69,637,000

Dividend Yield

PE Ratio

-5.06

Earnings Per Share (EPS)

-0.37

Revenue

Net Profit

-25.47M

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.medicenna.com

Headquarters

Toronto, Ontario, Can

Founded

Medicenna Therapeutics Corp is listed in the Biological Pds,ex Diagnstics sector of the Toronto Stock Exchange with ticker MDNA. The last closing price for Medicenna Therapeutics was $1.84. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 0.385 to $ 2.98.

Medicenna Therapeutics currently has 69,637,000 shares in issue. The market capitalisation of Medicenna Therapeutics is $128.13 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -5.06.

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive...

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck’s (known as MSD outside of the US and...

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells...

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression...

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression...

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor...

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna...

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.13	7.55813953488	1.72	1.98	1.65	53155	1.74269414	CS
4	0.09	5.11363636364	1.76	2.14	1.6	61249	1.82263453	CS
12	-0.02	-1.06951871658	1.87	2.62	1.27	81978	1.98023637	CS
26	-0.08	-4.14507772021	1.93	2.62	1.27	74052	2.03452876	CS
52	1.405	315.730337079	0.445	2.98	0.385	102603	1.86191423	CS
156	-0.42	-18.5022026432	2.27	2.98	0.215	63535	1.4439818	CS
260	-0.79	-29.9242424242	2.64	7.25	0.215	73483	2.76585562	CS

MDNA - Frequently Asked Questions (FAQ)

What is the current Medicenna Therapeutics share price?

The current share price of Medicenna Therapeutics is $ 1.85

How many Medicenna Therapeutics shares are in issue?

Medicenna Therapeutics has 69,637,000 shares in issue

What is the market cap of Medicenna Therapeutics?

The market capitalisation of Medicenna Therapeutics is CAD 128.13M

What is the 1 year trading range for Medicenna Therapeutics share price?

Medicenna Therapeutics has traded in the range of $ 0.385 to $ 2.98 during the past year

What is the PE ratio of Medicenna Therapeutics?

The price to earnings ratio of Medicenna Therapeutics is -5.06

What is the reporting currency for Medicenna Therapeutics?

Medicenna Therapeutics reports financial results in CAD

What is the latest annual profit for Medicenna Therapeutics?

The latest annual profit of Medicenna Therapeutics is CAD -25.47M

What is the registered address of Medicenna Therapeutics?

The registered address for Medicenna Therapeutics is 200 - 1920 YONGE STREET, TORONTO, ONTARIO, M4S 3E2

What is the Medicenna Therapeutics website address?

The website address for Medicenna Therapeutics is www.medicenna.com

Which industry sector does Medicenna Therapeutics operate in?

Medicenna Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
GMTNGold Mountain Mining Corp	$ 0.035 (16.67%)	10k
XLYAuxly Cannabis Group Inc	$ 0.035 (16.67%)	378.93k
PPRPrairie Provident Resources Inc	$ 0.035 (16.67%)	390k
WRXWestern Resources Corp	$ 0.04 (14.29%)	3k
GFRGreenfire Resources Ltd	$ 10.09 (13.37%)	31.9k
RTGRTG Mining Inc	$ 0.025 (-37.50%)	100k
NCFNorthcliff Resources Ltd	$ 0.02 (-20.00%)	1.03M
KLSKelso Technologies Inc	$ 0.11 (-15.38%)	3.5k
AVLAvalon Advanced Materials Inc	$ 0.035 (-12.50%)	114k
YRBYorbeau Resources Inc	$ 0.035 (-12.50%)	110k
TTelus Corp	$ 19.45 (-1.52%)	4.87M
BBBlackBerry Limited	$ 5.65 (4.05%)	3.61M
ABXBarrick Gold Corporation	$ 22.55 (0.71%)	3.57M
BITFBitfarms Ltd	$ 2.45 (6.06%)	3.26M
FCUFission Uranium Corp	$ 0.72 (-2.70%)	2.54M